Novavax, Inc. (NVAX) Balance Sheet

The sequential decline in total assets, from $1.8B to $955.6M over eight quarters, reflects both cash consumption and a reduction in receivables as revenue contracted. The equity position deteriorated from a positive $37.6M in 2025Q2 to a negative $190.7M by 2026Q2, driven by cumulative net losses and the absence of profitable quarters. This trajectory suggests the balance sheet is weakening, with the company relying on debt and cash reserves to fund operations, which may not be sustainable if revenue does not recover.

The company's debt has grown by roughly 30% over the past year, even as total assets shrank, indicating that borrowing is funding operational cash burn. With equity negative, the debt-to-equity ratio is not calculable, but the absolute debt level relative to the shrinking asset base suggests increasing financial risk. This leverage appears necessity-driven rather than strategic, as the company lacks the profitability to service debt from operations, and investors should monitor refinancing risk given the volatile cash flows.

The dramatic reduction in net PP&E suggests significant asset write-downs or disposals, likely reflecting the scaling back of manufacturing capacity as COVID vaccine demand waned. Goodwill has remained relatively stable, but its size relative to total assets has increased to about 12%, raising the risk of future impairment if the company's market value continues to decline. The asset mix is shifting toward intangibles and cash, which may indicate a pivot to a more asset-light model, but the write-downs signal that prior investments have not generated expected returns.

The equity position has been negative for most of the past ten quarters, with the exception of a brief positive in 2025Q2. Retained earnings have deteriorated from -$4.4B to -$4.6B, indicating ongoing losses despite occasional profitable quarters. The company has not engaged in significant buybacks or dividends, so the equity decline is purely from operational losses. This negative equity suggests that the company is technically insolvent on a book basis, though it continues to operate with cash and debt, which may concern investors about long-term viability.

The current ratio has remained above 2.0 in recent quarters, suggesting adequate short-term liquidity relative to current liabilities. However, the absolute cash balance has declined by over 70% from its peak, and with operating cash flow negative in most quarters, the company may have limited runway. The improvement in current ratio is partly due to a reduction in current liabilities, but the shrinking cash pile and ongoing burn rate indicate that the company may need to raise additional capital or cut costs to avoid a liquidity crunch.

The dramatic decline in deferred revenue suggests that the company has largely fulfilled its existing contractual obligations and is not generating new advance payments, which is consistent with the overall revenue decline. This metric is a leading indicator of future revenue, and its collapse implies that near-term revenue will remain depressed unless new orders materialize. The lack of deferred revenue also reduces the company's ability to fund operations with customer prepayments, increasing reliance on cash reserves and external financing.